As we posted yesterday, Amgen has filed a brief in opposition to Sandoz’s petition to the Supreme Court for review of the Federal Circuit’s decision in Amgen v. Sandoz. Amgen’s brief is now available here.
The Biosimilars Council also filed a brief, as amicus curiae in support of Sandoz’s petition. Their amicus brief is available here.
Stay tuned for further updates and analysis from the Big Molecule Watch.